US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

21.80

+0.80503.84%

Volume:5K

Turnover:117.04K

Market Cap:49.37M

PE:- -

High:21.80

Open:21.18

Low:21.15

Close:20.99

52wk High:27.02

52wk Low:15.63

Shares:2.26M

Float Shares:2.26M

Volume Ratio:0.45

T/O Rate:0.24%

Dividend:1.68

Dividend Rate:7.72%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GH Research to Present GH001 Depression Trial Data at ECNP 2026 Meeting

Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study

Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50

THOMSON REUTERS

Ballard Mining Launches $45 Million Share Placement and SPP to Fund Gold Projects

Cynata defines target market for new options in capital raising

Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

Clearmind Medicine submits psychedelic therapy recommendations to FDA

TZ Limited shares halted ahead of material capital raising

Canterbury Resources Raises $564,000 to Advance Monto Exploration

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105

NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial

Vaxcyte data hit ‘blue-sky’ case, says Jefferies

Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31

Surefire Resources Plans Placement of 45 Million New Shares

Surefire Resources launches A$2.7m equity raising to advance WA gold projects

Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

BioAge Labs initiates Phase 2 trial for BGE-102

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/PSIL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":21.795,"timestamp":1791563651777,"preClose":20.99,"halted":0,"volume":5445,"delay":0,"changeRate":0.03835159599809449,"floatShares":2264976,"shares":2264976,"eps":0,"marketStatus":"Trading","change":0.805,"latestTime":"10-09 12:35:29 EDT","open":21.18,"high":21.8,"low":21.15,"amount":117043.42765499999,"amplitude":0.030967,"askPrice":22,"askSize":100,"bidPrice":21.59,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":20.99,"sharesOutstanding":1184976,"nav":21.291,"aum":48224450.04,"dividendRate":0.077238,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.99,"preClose":20.99,"latestTime":"07:00 EDT","volume":16,"amount":335.84,"timestamp":1791543613403,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":20.96,"preClose":20.99,"latestTime":"19:40 EDT","volume":250,"amount":5235.67,"timestamp":1791502820850,"change":-0.03,"changeRate":-0.001429,"amplitude":0.001429},"volumeRatio":0.446934,"impliedVol":0.3795,"impliedVolPercentile":0.5857},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2264976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.446934,"shares":2264976,"dividePrice":1.6834,"high":21.8,"amplitude":0.030967,"preClose":20.99,"low":21.15,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":21.795,"eps":0,"divideRate":0.077238,"volume":5445,"delay":0,"ttmEps":0,"open":21.18,"prevYearClose":17.17,"prevWeekClose":21.85,"prevMonthClose":22.5,"prevQuarterClose":22.5,"fiveDayClose":21.85,"twentyDayClose":24.7682,"sixtyDayClose":24.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674856377","title":"GH Research to Present GH001 Depression Trial Data at ECNP 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856377","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856377?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:02","pubTimestamp":1791543739,"startTime":"0","endTime":"0","summary":"GH Research to present GH001 depression trial data at ECNP 2026 meetingGH Research plc set three posters for ECNP 2026 featuring data from its GH001-TRD-201 and GH001-BD-202 depression trials.Results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL3Qbv87:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4007","BK4539","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674090940","title":"Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2674090940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674090940?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:31","pubTimestamp":1791477107,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals ($MIRM) announced an update on their ongoing clinical study. The AZURE-2 Phase 3 trial from Mirum Pharmaceuticals, Inc. tests...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mirums-azure-2-trial-pits-brelovitug-against-bulevirtide-in-high-stakes-hepatitis-d-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mirums-azure-2-trial-pits-brelovitug-against-bulevirtide-in-high-stakes-hepatitis-d-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079126","title":"Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079126?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457599,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U1FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","MEDX","BK4139","ALKS","PSCH","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673468070","title":"Ballard Mining Launches $45 Million Share Placement and SPP to Fund Gold Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2673468070","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673468070?lang=en_us&edition=fundamental","pubTime":"2026-10-08 07:37","pubTimestamp":1791416250,"startTime":"0","endTime":"0","summary":"The latest update is out from Ballard Mining Limited ( ($AU:BM1) ). Ballard Mining Limited has launched a capital raising initiative comprising a n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ballard-mining-launches-45-million-share-placement-and-spp-to-fund-gold-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ballard-mining-launches-45-million-share-placement-and-spp-to-fund-gold-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673004531","title":"Cynata defines target market for new options in capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2673004531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673004531?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:38","pubTimestamp":1791412685,"startTime":"0","endTime":"0","summary":"An announcement from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Cynata Therapeutics has issued a target market determination for n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cynata-defines-target-market-for-new-options-in-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cynata-defines-target-market-for-new-options-in-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","PSIL","IBRN","MEDX","BK4139","ABVC","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673656016","title":"Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673656016","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673656016?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:00","pubTimestamp":1791381622,"startTime":"0","endTime":"0","summary":"WSW, NY, October 7th, 2026, FinanceWire The former Gilead and Amgen commercial leader takes her seat as Entera’s Phase 3 trial nears its init...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","JEPQ","NVIW.SI","BK4534","LU0889565916.HKD","ONEQ","QYLG","SQQQ","BBH","MNQmain","LU0320765992.SGD","NDX","NQmain","IE00BFTCPJ56.SGD","TQQQ","QID","03086",".IXIC","PSQ","QQQM","AMGN","PBE","LU1983299246.USD","ENTX","IYW","QLD","IBB","QQQJ","QQQ","TECS","IE0002141913.USD","IBBQ","TQQY","TBXU","LU1057294990.SGD","PSIL","GPIQ","BBC","LU0122379950.USD","PJP","QQQE","IE00BJT1NW94.SGD","BIB","BK4599","FTEC","QQQA","BK4139","QDTE","QQQY","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673159350","title":"Clearmind Medicine submits psychedelic therapy recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673159350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673159350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:25","pubTimestamp":1791379525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CMND","LABU","PSIL","BK4007","PSYK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673660180","title":"TZ Limited shares halted ahead of material capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2673660180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673660180?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:34","pubTimestamp":1791326069,"startTime":"0","endTime":"0","summary":"The latest announcement is out from TZ Limited ( ($AU:TZL) ). TZ Limited has requested and been granted a trading halt on its shares on the Austral...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tz-limited-shares-halted-ahead-of-material-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tz-limited-shares-halted-ahead-of-material-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066214","title":"Canterbury Resources Raises $564,000 to Advance Monto Exploration","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066214?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:10","pubTimestamp":1791324648,"startTime":"0","endTime":"0","summary":"Canterbury Resources Ltd. ( ($AU:CBY) ) just unveiled an update. Canterbury Resources has completed a strategic capital raising of $564,000 via a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/canterbury-resources-raises-564000-to-advance-monto-exploration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/canterbury-resources-raises-564000-to-advance-monto-exploration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051961","title":"ArriVent says Phase 3 firmonertinib trial did not meet endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051961?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:13","pubTimestamp":1791292413,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, loca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705514","title":"Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705514","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705514?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:35","pubTimestamp":1791286532,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","HYLG","KAPA","BK4139","PSIL","KAIR","IDNA","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084771","title":"NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084771","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084771?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:01","pubTimestamp":1791234103,"startTime":"0","endTime":"0","summary":"NRx Defense Systems wins initial $11.18 million DARPA prime contract for SPARC-TMS depression trialNRx Defense Systems, a NRX Pharmaceuticals unit, won a DARPA prime contract worth USD 11.18 million f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1b0rVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673088978","title":"Vaxcyte data hit ‘blue-sky’ case, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673088978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673088978?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:55","pubTimestamp":1791208523,"startTime":"0","endTime":"0","summary":"After Vaxcyte (PCVX) announced topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating its VAX-31 31-valent pneumococcal conjugate v...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4139","BBC","IE0009354923.USD","PCVX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709724","title":"Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709724","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709724?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:10","pubTimestamp":1791195037,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","LU0053671581.USD","BBC","IE0009354923.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776060","title":"Surefire Resources Plans Placement of 45 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776060?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:32","pubTimestamp":1791156742,"startTime":"0","endTime":"0","summary":"The latest update is out from Surefire Resources NL ( ($AU:SRN) ). Surefire Resources NL has notified the ASX of a proposed capital raising via an ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/surefire-resources-plans-placement-of-45-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/surefire-resources-plans-placement-of-45-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673877609","title":"Surefire Resources launches A$2.7m equity raising to advance WA gold projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2673877609","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673877609?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:32","pubTimestamp":1791156734,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Surefire Resources NL ( ($AU:SRN) ). Surefire Resources NL has launched a capital raising of up to A$2.61 milli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/surefire-resources-launches-a2-7m-equity-raising-to-advance-wa-gold-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/surefire-resources-launches-a2-7m-equity-raising-to-advance-wa-gold-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHYS","BEGS","DULL","JNUG","UGL","PSIL","BAR","DUST","DGP","SGDM","GDXJ","GLDY","XME","GDX","GDXU","NUGT","OUNZ","IAUI","DBC","YGLD","FGDL","AAAU","CEF","IGLD","BTGD","GLTR","IAU","PPI","SHNY","GOLY","KGLD","RING","JDST","SGOL","1OZmain","DZZ","GDXD","IAUM","GDXW","GOAU","GLDM","GLD","GDXY","GBUG","GLL","USG","UYM","DGZ","BGLD","PICK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776067","title":"Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776067?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:22","pubTimestamp":1791156146,"startTime":"0","endTime":"0","summary":"An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported new analyses from its Phase 2 trial of AT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672974104","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974104","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974104?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:23","pubTimestamp":1790979782,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $83,464.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Oct. 2, 2026.Sale price USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6fSlzc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672741591","title":"BioAge Labs initiates Phase 2 trial for BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2672741591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672741591?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:54","pubTimestamp":1790974488,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ( ($BIOA) ) just unveiled an update. BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-initiates-phase-2-trial-for-bge-102?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-initiates-phase-2-trial-for-bge-102?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4007","PSIL","BIOA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}